Slide 1: Pfizer Oncology Analyst Call
Pfizer Oncology Analyst Call June 8, 2016 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Our discussions during this conference call will include forward-looking statements about, among other things, our oncology strategy, our in-line and pipeline oncology portfolio, including Ibrance, avelumab, our immuno- oncology portfolio, and other in-line products and pr
Slide 3: Pfizer Oncology Vision: To be a Leader in Oncology by Speeding Cures
Pfizer Oncology Vision Leadership To be a Leader A serious commitment to being leaders in Oncology in Oncology by Accessible Speeding Cures Establish the value of these medicines so patients everywhere can access them and Accessible Speed Breakthrough Bring these medicines to patients as quickly and
Slide 4: Focused To Achieve Our Goals
Focused To Achieve Our Goals To be a Leader in Oncology by Speeding Cures and Accessible Breakthrough Medicines to Patients, Redefining Life with Cancer Key Focus Areas Create a Immuno- Ibrance “Breakthrough” Oncology Pipeline • Avelumab: Partnerships • Partner with and • Agile Discovery backbone PD
Slide 5: Beyond Monotherapy PD-1/PD-L1, Significant Untapped Need Remains
Beyond Monotherapy PD/ PD-L1, Significant Untapped Need Remains for the Vast Majority Response Rates Can Vary by "Bridging the Gap" Requires Molecule and Tumor Type ~100% • Commitment to transformational 100 break-through clinical impact for PD-(L)1 Monotherapy ORR % 90 80 patients through rational
Slide 6: Pfizer Oncology's Biggest ASCO Yet: 50 Abstracts Across 15 Tumor Types
Key Data at ASCO 2016 Pfizer Oncology’s Biggest ASCO Yet 50 Abstracts Accepted Across 15 Tumor Types Highlights • Palbociclib: Phase III PALOMA-2 trial demonstrated impact of adding palbociclib to letrozole as 1L therapy for women with ER+/HER2- advanced BC 16 Avelumab 11 IBRANCE, 7 • Utomilumab + P
Slide 7: Pembrolizumab + Utomilumab: Evidence of Immune Response
Key Data at ASCO 2016: Combination Immuno-Oncology Pembrolizumab + Utomilumab: Evidence of Immune Response Lymphocyte Subsets Observed at Cycle 5 Day 1 • Strong pre-clinical rationale for targeting both PD-1 + 4-1BB • Patients with clinical response had an increase in total lymphocytes, activated an
Slide 8: Pembrolizumab + Utomilumab: Evidence of Clinical Activity
Key Data at ASCO 2016: Combination Immuno-Oncology Pembrolizumab + Utomilumab: Evidence of Clinical Activity Waterfall Plot: Maximum Tumor Shrinkage Abstract 3002 Phase 1b study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors Presenter: Anthony W. Tolcher, MD,
Slide 9: Avelumab: Efficacy in Merkel Cell Carcinoma (previously treated)
Key Data at ASCO 2016: Avelumab: Efficacy in Merkel Cell Carcinoma (previously treated) Patients with Baseline and at Least One Post-baseline Target Lesion Assessment (n=65) Baseline At 5.3 Months Abstract 9508 Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma prev
Slide 10: Significant Oncology Pipeline Opportunities in the Next Five Years
Significant Oncology Pipeline Opportunities in the Next Five Years In-Line Near-term Medium-term inotuzumab ozogamicin lorlatinib avelumab 4-1BB (lead indication) glasdegib Mylotarg avelumab dacomitinib (several indications) Today 1-2 Years 2-5 Years 10